MAL2 and hepatocellular carcinoma: Therefore, it is hypothesized that MAL2 might facilitate trafficking of IL7 and its cognate receptors to the plasma membrane and contribute to HCC-associated Sorafenib resistance by upregulating important survival signaling pathways.